Traumatic articular cartilage lesions have a limited capacity to heal. We tested the hypothesis that overexpression of a human insulin-like growth factor I (IGF-I) cDNA by transplanted articular chondrocytes enhances the repair of fullthickness (osteochondral) cartilage defects in vivo. Lapine articular chondrocytes were transfected with expression plasmid vectors containing the cDNA for the Escherichia coli lacZ gene or the human IGF-I gene and were encapsulated in alginate. The expression patterns of the transgenes in these implants were monitored in vitro for 36 days. Transfected allogeneic chondrocytes in alginate were transplanted into osteochondral defects in the trochlear groove of rabbits. At three and 14 weeks, the quality of articular cartilage repair was evaluated qualitatively and quantitatively. In vitro, IGF-I secretion by implants constructed from IGF-I-transfected chondrocytes and alginate was 123.2722.3 ng/10 7 cells/24 h at day 4 post transfection and remained elevated at day 36, the longest time point evaluated. In vivo, transplantation of IGF-I implants improved articular cartilage repair and accelerated the formation of the subchondral bone at both time points compared to lacZ implants. The data indicate that allogeneic chondrocytes, transfected by a nonviral method and cultured in alginate, are able to secrete biologically relevant amounts of IGF-I over a prolonged period of time in vitro. The data further demonstrate that implantation of these composites into deep articular cartilage defects is sufficient to augment cartilage defect repair in vivo. These results suggest that therapeutic growth factor gene delivery using encapsulated and transplanted genetically modified chondrocytes may be applicable to sites of focal articular cartilage damage.
Introduction
Traumatic articular cartilage defects do not heal spontaneously. Efforts to achieve repair of these lesions have been limited by the challenge of stimulating the resident cells to form new cartilage. When cell-based therapy is employed, there arises the additional challenge of retaining the transplanted cells in the defect. 1 The initial healing response to an osteochondral articular cartilage defect is mediated, in part, by cell signaling polypeptides that act on cells derived either from the joint cavity 2 or the bone marrow. 3 Such polypeptides influence the rate of articular cartilage repair. [3] [4] [5] [6] Insulin-like growth factor-I (IGF-I) is a 7.6 kDa polypeptide growth factor that stimulates both matrix synthesis and cell proliferation of chondrocytes. In particular, it increases chondrocyte production of proteoglycan and type-II collagen, two principal constituents of cartilage. [7] [8] [9] The exogenous administration of human IGF-I has been reported to enhance the cell-based repair of articular cartilage defects. 3, 6 Delivery of recombinant human IGF-I protein to articular cartilage has been achieved by intra-articular injection, 10 by supplementing a fibrin clot with IGF-I 3 and by combining composites of chondrocytes and polymerized fibrin with IGF-I. 6 The development of IGF-I as a therapeutic agent for articular cartilage disorders has been restrained by its short intra-articular residence time and the intrinsic paucity of articular chondrocytes to serve as target cells. Genetically engineered chondrocytes could be used to both secrete a therapeutic growth factor and to supply a cell population capable of responding to an exogenous repair stimulus. We previously reported that overexpression of a human IGF-I cDNA promotes new tissue formation in an ex vivo model of articular chondrocyte transplantation 11 and enhances tissue engineering of cartilage. 12 When luciferase-transfected chondrocytes embedded in alginate were implanted into articular cartilage defects in vivo, reporter gene expression persisted in articular defects for at least 32 days. 13 It remains unknown if chondrocyte transfection with a potentially therapeutic gene such as IGF-I leads to secretion of the recombinant protein following cell encapsulation in alginate in vitro and whether such overexpression modifies articular cartilage repair when transplanted into sites of articular cartilage damage in vivo. In this study, we tested the hypothesis that overexpression of human IGF-I by articular chondrocytes transplanted in a hydrogel into osteochondral cartilage defects enhances cartilage repair in vivo.
Results

IGF-I production by transfected chondrocytes encapsulated in alginate in vitro
Chondrocyte-alginate implants were characterized and the time course of recombinant IGF-I production was assessed in vitro. Lapine articular chondrocytes were transfected in monolayer culture with expression plasmid vectors carrying either the Escherichia coli lacZ gene or a human IGF-I cDNA using the nonliposomal lipid formulation FuGENE 6. At 1 day after transfection, the modified chondrocytes were encapsulated in the hydrogel, alginate. At the time of encapsulation, implants constructed from lacZ-or IGF-I transfected chondrocytes and alginate (termed lacZ or IGF-I implants) had a mean diameter of 3.270.3 and 3.270.5 mm, respectively, and a cell viability of 84. 4 Figure  1a and b). The total number of chondrocytes per implant in the lacZ-transfected group declined 14% over the 36 days of in vitro cultivation. In contrast, the total number of chondrocytes in IGF-I implants increased 24% over this time period (Table 1 , Figure 1c and d) .
Mean transfection efficiency as determined by X-gal staining of lacZ-transfected chondrocytes 2 days following transfection was 35.777.9%. At all time points tested, conditioned medium from lacZ implants contained p10.876.7 ng IGF-I per 1 Â 10 7 viable cells/24 h. In comparison, IGF-I implants produced up to 123.27 22.3 ng IGF-I per 1 Â 10 7 viable cells/24 h. This maximum was observed on day 4 with a decrease to 28.474.2 at 36 days (Table 1) .
Macroscopic findings
We next tested the hypothesis that chondrocyte-alginate implants overexpressing IGF-I augment the repair of Figure 1 Representative histologic sections of lacZ implants (left) and IGF-I implants (right) stained with hematoxylin and eosin (a-d) or a polyclonal anti-caspase-3 IgG (e, f). The chondrocyte-alginate implants were cultured in vitro for 2 (a, b) or 36 days (c, d) in serum-free medium. Over the time of in vitro cultivation, cellularity was preserved and matrix staining increased. (e, f) Histologic sections of a lacZ implant (e) and an IGF-I implant (f) transplanted into an osteochondral defect after 3 weeks in vivo. Cells that underwent apoptosis are distinguishable by their brown color. Photomicrographs were obtained using standardized photographic parameters, including light intensity. Original magnifications Â 200 (a-d) and Â 250 (e, f). Lapine articular chondrocytes transfected with pCMVlacZ or pCMVhIGF-I were encapsulated in alginate on day 1 post transfection and kept in basal medium containing 2% FBS for 36 days. Chondrocyte-alginate implants were collected at the denoted times. Released chondrocytes were counted and their viability was assessed using a Neubauer chamber and trypan blue exclusion staining, respectively. IGF-I protein was assessed as described in Materials and methods. Data are expressed as mean7standard deviations per time point of six samples per condition.
Enhanced cartilage repair by IGF-I overexpression H Madry et al articular cartilage defects in vivo. At 1 day after encapsulation (2 days after transfection), lacZ or IGF-I implants were press-fit into osteochondral defects in each patellar groove of 12 rabbits. Animals were euthanized and defects were analyzed three and 14 weeks following surgery. At 3 weeks after transplantation, the margins of the defects were visible and the new tissue in all knees was whiter than the surrounding host cartilage. At 14 weeks after transfection, the color of the defects was similar to the surrounding articular cartilage and the margins of the defects were difficult to discern. No joint effusion, osteophytes or adhesions were observed at either time point. Macroscopically, there were no descriptive differences between knee joints receiving lacZ and IGF-I implants at either time point.
Microscopic evaluation of synovium
There was no significant difference in the thickness or architecture of synovial villi or in the presence of inflammatory cell infiltrates in knees receiving lacZ implants compared to IGF-I implants at either 3 weeks (P40.05) or 14 weeks (P40.05) ( Table 2 ).
Immunohistochemical analysis
At 3 weeks after transfection, immunoreactivity to type II collagen was negative in the repair tissue of both groups (Figure 2 ). At 14 weeks after transfection, immunoreactivity to type II collagen in the repair tissue was subjectively greater in both groups than at 3 weeks following transfection (Figure 3 ). At both 3 and 14 weeks, immunoreactivity to type II collagen was subjectively not different in the matrix of defects receiving IGF-I implants than in defects treated with lacZ implants.
Histological grading
Articular cartilage repair was evaluated using a previously published histological grading system developed to quantitate repair of articular cartilage defects. 4, 5 This grading system is based on eight parameters ( Table 3) that are scored individually. The individual scores are then combined. The resulting total score ranges from 0 points (normal articular cartilage) to 31 points (no repair tissue). At 3 weeks following surgery, the mean score for each of the individual histological parameters was lower (more normal) for defects treated with IGF-I implants than for defects treated with lacZ implants (Po0.01 to Po0.0001) (Table 4) . Similarly, the mean total score at 3 weeks was significantly lower for defects treated with IGF-I implants than for defects treated with lacZ implants (Po0.0001; n ¼ 6) (Table 4, Figure 2) . At 14 weeks, the mean score for each individual parameter continued to be significantly better in defects that were treated with IGF-I implants than those that Immunoreactivity to type II collagen is present in the native articular cartilage and absent in the repair tissue of both groups (e, f). The sections illustrated were taken from defects having a histological rating equal to the mean score for its respective treatment group. Photomicrographs were obtained using standardized photographic parameters, including light intensity. Original magnifications Â 20 (a, b) or Â 100 (c-h).
Enhanced cartilage repair by IGF-I overexpression H Madry et al received lacZ implants (Po0.01 to Po0.0001) ( Table 5 ). The mean total score at 14 weeks also remained significantly better in the IGF-I implant group (Po0.0001; n ¼ 5) (Table 5 , Figure 3 ). Between 3 weeks and 14 weeks in vivo, improvement in the score of individual histological parameters was observed for safranin O staining (lacZ and IGF-I implants; Po0.01), cell morphology (IGF-I implants; Po0.01), formation of subchondral bone (lacZ and IGF-I implants; Po0.01) and tidemark (lacZ and IGF-I implants; Po0.01). All other individual parameters included in the histological scale were not significantly different at these time points. The mean total score for defects treated with lacZ and IGF-I implants improved significantly during this time period (Po0.01).
Over the course of the in vivo experiment, all chondrocyte-alginate implants were found below the newly formed tidemark. To study the survival of the chondrocytes within the alginate, we examined the activity of caspase-3, a key enzyme activated in cells undergoing apoptosis. Several chondrocytes in lacZ and IGF-I implants were positive for activated caspase-3 after 3 weeks (Figure 1e and f). To evaluate the fate of the implants, the area occupied by lacZ and IGF-I implants excluding any ingrown tissue was measured. The area occupied by lacZ and IGF-I implants after 3 weeks was 1.370.4 and 1.070.2 mm 2 , respectively. At 14 weeks in vivo, the area occupied by lacZ and IGF-I implants was 0.570.2 and 0.370.1 mm 2 , respectively (P40.05 for both time points). These data suggest that the alginate is progressively resorbed following placement in this subchondral location.
Discussion
A major challenge in articular cartilage regeneration is to identify both an effective therapeutic agent and a responsive target cell population. An additional challenge is the identification of delivery systems for the therapeutic agent and/or cells. Nearly all animal experiments for articular cartilage repair have required Articular cartilage repair was quantitated using a histological grading system previously published by Sellers et al. 4, 5 This grading system is based on eight individual parameters. The individual scores are then added. The resulting total score ranges from 0 points (normal articular cartilage) to 31 points (empty defect with no repair tissue). Adapted from Sellers et al.
4,5
Enhanced cartilage repair by IGF-I overexpression H Madry et al relatively large, often repeated, doses of growth factors. [2] [3] [4] [5] [6] 10 This is consistent with a relatively rapid clearance of otherwise potent therapeutic molecules and suggests a value for local growth factor production. Gene therapy at the site of articular cartilage repair is a clinically relevant application of gene transfer technology and represents a potential solution to these problems. In this study, we tested the hypothesis that overexpression of a human IGF-I cDNA by articular chondrocytes transplanted in a hydrogel enhances the repair of full-thickness cartilage defects in vivo. The data indicate that chondrocytes transfected by a lipid-based method with a human IGF-I expression plasmid vector and encapsulated in alginate in vitro secrete relevant amounts of recombinant human IGF-I protein. The data further demonstrate that transplantation of these cells in alginate enhances the repair of full-thickness osteochondral cartilage defects in vivo.
We selected IGF-I for these studies based on previous work demonstrating that this factor augments chondrocyte mitotic activity, proteoglycan and type-II collagen synthesis, [7] [8] [9] new tissue formation by transplanted chondrocytes, 11 and the structural and functional properties of tissue-engineered cartilage. 12 Several in vivo studies further support the selection of IGF-I as a candidate for articular cartilage repair. 3, 6 In a canine model of osteoarthritis, intra-articular delivery of 2 mg IGF-I three times per week for 3 weeks led to improvement in indices of cartilage damage. 10 Treatment of chondral (partial thickness) defects in adult rabbit and Yucatan minipig models with 50 ng/ml IGF-I applied in a fibrin clot improved the cellularity of the repair tissue. 2 In a rat chondral (partial thickness) model, rib perichondrial cells containing an adenoviral IGF-I vector improved short-term repair when delivered in a fibrin clot.
14 Treatment of extensive osteochondral (full-thickness) defects with 25 mg IGF-I, applied in a fibrin composite, enhanced repair in a horse model, 3 as did IGF-I coupled with cell-based treatment. 6 The present approach circumvents the high initial peak that occurs after the delivery of a peptide4 and bypasses the hindrance of the rapid clearance of IGF-I. In the present study, 6.372.6 Â 10 4 viable chondrocytes overexpressing IGF-I embedded in alginate were transplanted directly into an osteochondral articular cartilage defect. Such local administration of these modified cells to the site of the injury may be important since no morphologic changes in articular cartilage were seen when 1 Â 10 6 fibroblasts transduced ex vivo with a recombinant adenovirus carrying a human IGF-I cDNA were injected into the knee joint in a mouse model. 15 In such cell-based Effects of IGF-I gene transfer at 3 weeks on histological grading of repair tissue. Each category and total score is based on the average of two independent evaluators. Points for each category and total score were compared between IGF-I and lacZ groups using a mixed general linear model with repeated measures (knees nested within the same animals; CI ¼ confidence interval). Means indicate the estimated scores in points for each category. Highly significant treatment effects were observed for each of the variables. Effects of IGF-I gene transfer at 14 weeks on histological grading of repair tissue. Each category and total score is based on the average of two independent evaluators. Points for each category and total score were compared between IGF-I and lacZ groups using a mixed general linear model with repeated measures (knees nested within the same animals; CI ¼ confidence interval). Means indicate the estimated scores in points for each category. Highly significant treatment effects were observed for each of the variables.
Enhanced cartilage repair by IGF-I overexpression H Madry et al therapies, the overexpressed gene product is unlikely to act in isolation. Potential interaction between the overexpressed IGF-I and factors produced by the transplanted and host cells in this model remain to be elucidated. The alginate system 16, 17 was selected because of its well-characterized ability to maintain the differentiated phenotype of chondrocytes, 18, 19 the comparability of its negative charge density to that of native cartilage matrix, 20 its stability over short time periods 16 and its potential to allow allogeneic cell transplantation. 21 Alginate has been successfully used to deliver bone marrow-derived cells 22 and chondrocytes 23 to osteochondral articular cartilage defects in a rabbit model. In addition, alginate has been shown not to influence osteoarticular defect healing in the rabbit knee 24 and may protect transplanted allogeneic cells from immune rejection. 25 Furthermore, chondrocytes embedded in alginate are capable of expressing a transgene for at least 6 weeks in vitro 26 and 32 days in vivo even when nonviral, nonintegrating gene delivery is used. 13 Finally, alginate has already been used in human studies. 27 The present data indicate that transfection with an IGF-I expression plasmid vector does not impair chondrocyte viability when encapsulated in alginate. The data further indicate that transfection with an IGF-I expression plasmid vector is sufficient to induce cell proliferation in this in vitro model system as determined by an increased cell number after 36 days of cultivation.
Chondrocytes embedded in alginate have been reported not to significantly participate in the generation of the repair tissue in an osteochondral articular cartilage defect. 23 The data from the present study suggest that the IGF-I released by the cells within the alginate achieved biologically relevant concentrations in vitro and was sufficient to stimulate osteochondral defect repair in vivo. Chondrocytes were selected for these studies because they are adapted to the avascular environment of the joint and normally exist in suspension in a matrix. The fate of the transplanted cells in these full-thickness defects is uncertain. The data from the present study indicate that apoptotic cell death affects a part of the transplanted cells. Other cells may have undergone necrosis, migration or other fate following transplantation. It is possible that chondrocyte survival within the implants was mediated by the overexpression of IGF-I. 28 Transgene expression in vivo 13 suggests that some cells remain alive, while implant resorption suggests eventual cell removal. These results are consistent with the observation in prior studies that chondrocytes placed in these full-thickness defects do not appear to remain for long time periods. 23, 29 We employed full-thickness, osteochondral defects because these are analogous to the common clinical circumstance in which defects penetrate, or are treated by methods that penetrate, the subchondral bone.
1 These methods permit marrow-derived cells to participate in the repair process. IGF-I has been shown to promote the differentiation of marrow-derived 3 and synovialderived 2 cells into cartilage. Thus, the augmented repair may reflect the action of IGF-I produced by the transplanted cells on marrow-derived cells, synovialderived cells, the transplanted chondrocytes or all of these cell types.
The model system of an osteochondral articular cartilage defect in the rabbit knee joint was chosen based on its widespread use as a tool to study articular cartilage repair. 2, 4, 5, [30] [31] [32] [33] It is important to note that there is insufficient intrinsic healing of the defects in this model system, as evidenced by the high (abnormal) score values in the lacZ control group at both time points. We have previously demonstrated that recombinant genes can be introduced into osteochondral defects in vivo by transfected articular chondrocytes in alginate and that transgene expression remains present in vivo for at least 32 days post transfection. 13 Overexpression of human IGF-I by articular chondrocytes has been shown to increase cell proliferation and matrix synthesis as early as 5 days in an in vitro model of cartilage repair 11 and to enhance the functional properties of tissue-engineered cartilage as early as 28 days. 12 A mean residence time of 8 days was estimated for human bone morphogenic protein-2 (BMP-2) delivered in a collagen sponge to osteochondral cartilage defects in rabbits in vivo. 4 This relatively short time period was sufficient to elicit significant improvements in the histological appearance and composition of the repair tissue. 4 In the present study, improvements in articular cartilage repair were already apparent at 3 weeks. It is interesting to note that the magnitude of improvement in articular cartilage in the present study is similar to the enhancement obtained when recombinant human BMP-2 protein was applied in a collagen sponge. 5 We used a grading system developed specifically for the quantitative assessment of articular cartilage defect repair 4, 5 (Table 3) rather than a measure designed to assess arthritic changes. The scale is sensitive to change over time and has been used in this model to evaluate the effect of other cell-signaling molecules on articular cartilage repair. 4, 5 Indeed, significant improvements in articular cartilage repair were seen for both groups at the late time point of 14 weeks compared to 3 weeks. The improvements in cellular morphology and architecture observed in vivo within these defects are in agreement with our previous findings that IGF-I overexpression enhances cellularity and matrix formation in an in vitro model of articular chondrocyte transplantation.
11
Efforts to achieve effective articular cartilage repair in vivo have been hindered in part by difficulty in achieving integration of the newly formed tissue with the surrounding cartilage at the margins of the defect. 32 Articular cartilage defects treated with chondrocytes overexpressing IGF-I showed significantly better integration of the repair tissue at the interface with the surrounding normal articular cartilage than did control defects. Such integration appears to be important in establishing the biomechanical environment of both the repair and surrounding cartilage. 34 In summary, the data indicate that alginate is a suitable three-dimensional carrier for genetically modified allogeneic articular chondrocytes that allows for a prolonged secretion and release of bioactive recombinant human IGF-I in vitro. The data further demonstrate that a single application of such implants containing chondrocytes secreting recombinant human IGF-I to osteochondral articular cartilage defects is sufficient to augment articular cartilage repair for a prolonged period of time. These results suggest that therapeutic growth factor gene delivery via encapsulated and transplanted genetically 
Materials and methods
Materials
Reagents were obtained from Invitrogen/Gibco (Karlsruhe, Germany) unless otherwise indicated. Collagenase type I (activity: 232 U/mg) was from Biochrom (Berlin, Germany). Bovine testicular hyaluronidase and alginate were from Sigma (Munich, Germany). Plasticware was from Falcon (Becton Dickinson, Pont de Claix, France).
Cells, expression plasmid vectors and transfection
Articular cartilage was obtained from the knee and hip joints of male Chinchilla bastard rabbits (mean weight: 2.870.4 kg; Charles River, Sulzfeld, Germany). The animals were in their late juvenile stage according to post-mortem analysis of their distal femoral growth plate. The cartilage was washed, diced into 2.0 Â 2.0 Â 0.5 mm pieces and transferred to DMEM with 50 mg/ ml ascorbic acid, 100 U/ml penicillin G and 100 ml/ml streptomycin (basal medium) containing 0.02% collagenase at 371C in a humidified atmosphere with 10% CO 2 for 16 h. Isolated cells were filtered through a 125 mm mesh to remove undigested matrix. Cell number was determined by hemocytometry. Viability, as determined by trypan blue exclusion, always exceeded 90%. In vitro studies were based on optimized transfection of primary cultures of lapine articular chondrocytes using the nonliposomal lipid formulation FuGENE 6 (Roche, Mannheim, Germany) essentially as previously described. 13 Briefly, chondrocytes were transfected with endotoxin-free expression plasmid vectors carrying either the E. coli lacZ gene (pCMVlacZ; lacZ-transfected), 35 or a human IGF-I cDNA (pCMVhIGF-I; IGF-Itransfected) 11, 12 under the control of the human cytomegalovirus (CMV) immediate-early promoter/enhancer. Briefly, plasmid DNA was complexed with Fu-GENE6 in Opti-MEM and transferred to subconfluent chondrocyte monolayers. Cells were treated with 4 U/ml bovine testicular hyaluronidase 12 h before and during transfection. Transfections of chondrocytes for encapsulation in alginate were performed with chondrocytes at passage 2, 10-14 days after cell isolation, seeded at a density of 0.8 Â 10 6 cells/dish in basal medium containing 10% fetal bovine serum (growth medium) in 100 mm dishes. 13 
Construction of chondrocyte-alginate implants
To facilitate the transplantation of chondrocytes into articular cartilage defects, implants were made by using chondrocytes in the hydrogel, alginate. Transfected chondrocytes were encapsulated in alginate essentially as previously described. 13 Briefly, 1 day after transfection, chondrocytes were trypsinized, washed and suspended in 1.2% alginate in 0.15 M NaCl at 2 Â 10 6 cells/ ml. The cell suspension was then extruded into a 102 mM CaCl 2 solution at room temperature under constant shaking and the chondrocytes-alginate composite was allowed to polymerize for 10 min. The resulting implants were then washed twice in 0.15 M NaCl followed by two consecutive washes in basal medium and placed in growth medium (five implants/ml medium) that was changed three times per week and kept at 371C in a humidified atmosphere of 10% CO 2 . Implant diameters were measured 2 h after encapsulation using a microscope fitted with a micrometer scale. Cultured chondrocyte-alginate implants were assessed for cell number and viability at 2, 4, 7, 12, 24 and 36 days post transfection. Individual implants were solubilized by incubation in 100 ml 55 mM sodium citrate, 90 mM NaCl, pH 6.8 for 20 min at room temperature. Released chondrocytes were counted and their viability assessed using a Neubauer chamber and trypan blue exclusion staining based on 4 counts per sample. To determine IGF-I production by chondrocytes encapsulated in alginate, chondrocyte-alginate implants were individually cultivated in 96-well plates in growth medium. At the indicated time points, implants were washed twice in basal medium and the medium was replaced with 200 ml basal medium. After 24 h, the conditioned medium was collected, centrifuged to remove cell debris and stored at À801C.
Transplantation to articular cartilage defects in vivo
The Saarland Governmental Animal Care Committee approved all animal procedures. Rabbits (Charles River) were kept in air-conditioned rooms with constant temperatures and a regular light/dark scheme. They were fed a standard diet and received water ad libitum. A total of 12 male Chinchilla bastard rabbits (six animals per group) were anesthetized by intramuscular injection of Ketavet (0.75 mg/kg of body weight; Pharmacia & Upjohn, Erlangen, Germany) and Rompun (0.2 ml/kg of body weight; Bayer, Leverkusen, Germany). Ampicillin (Pfizer, Karlsruhe, Germany) was administered intramuscularly 2 h preoperatively at a dosage of 25 mg/kg of body weight. The knee joint was entered through a medial parapatellar approach. The patella was dislocated laterally and the knee flexed to 901. A cylindrical osteochondral cartilage defect was created in each patellar groove (n ¼ 24 defects) with a manual cannulated burr (3.2 mm in diameter; Synthes, Umkirch, Germany). Each defect was washed with saline and blotted dry. Chondrocyte-alginate implants were pressfit into the defects 1 day after encapsulation (2 days post transfection). Implants from one preparation were employed in all defects. Implants constructed from lacZ-transfected chondrocytes and alginate contained 6.970.9 Â 10 4 chondrocytes with a viability of 90.772.5%. Implants constructed from IGF-I-transfected chondrocytes and alginate contained 6.372.6 Â 10 4 chondrocytes with a viability of 87.171.9%.
The right and left knees alternately received lacZ-or IGF-I implants. The patella was reduced and the knee was put through a range of motion to assure the stability of the implants. The incisions were closed in layers. No postoperative immobilization was used and animals were allowed immediate full weight bearing. After 6 weeks postoperation, animals were allowed to climb and jump.
Gene transfer analyses
Mean transfection efficiency was assessed by X-gal staining of lacZ-transfected chondrocytes in monolayer culture as previously described. 35 To determine IGF-I
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Histological and immunohistochemical analysis
Alginate implants cultured in vitro were fixed in 10% phosphate-buffered formalin, embedded in paraffin, sectioned and submitted to histological analysis as described below. One rabbit was removed from the protocol because of death following a gastrointestinal infection at day 22 post operation. Three (n ¼ 6) and 14 weeks (n ¼ 5) after transfection, animals were euthanatized and the knee joints were exposed and examined grossly for synovitis, adhesions or other adverse reactions from the implants. The appearance of the repair tissue (color, integrity, contour) and articular surfaces was documented. Distal femurs were retrieved, fixed in 10% phosphate-buffered formalin, trimmed to 2.0 Â 1.5 Â 1.0 cm and decalcified. Paraffin-embedded frontal sections (5 mm) were stained with safranin O and hematoxylin and eosin according to routine histological protocols. To study activated caspase-3, sections were deparaffinized in xylene, passed through decreasing concentrations of ethanol, washed in PBS and submerged in 0.3% hydrogen peroxide for 30 min. After washing with PBS, sections were incubated in 0.1% Trypsin for 30 min, washed with PBS and blocked with 3% bovine serum albumin in PBS (blocking buffer) for 30 min. Sections then were incubated overnight at room temperature with a 1:50 dilution of a cleaved caspase-3 polyclonal antibody (Asp175; Cell Signaling Technology, Frankfurt, Germany). This antibody detects endogenous levels of only the short fragment (17/19 kDa) of activated caspase-3, but not of the full-length caspase-3. A biotinylated goat anti-mouse antibody was used as a secondary antibody for streptavidin-biotin complex peroxidase staining (1:200; LSAB 2 System HRP; DakoCytomation, Hamburg, Germany). Diaminobenzidine (DakoCytomation) was used as chromogen. Sections were counterstained with hemalaun and examined by light microscopy. For type-II collagen immunostaining, deparaffinized sections were submerged in 0.3% hydrogen peroxide for 30 min. After washing with PBS, sections were incubated in 0.1% Trypsin for 30 min, washed with PBS and blocked with blocking buffer for 30 min. Sections then were incubated with a 1:10 dilution of a monoclonal mouse anti-human type-II collagen IgG (Medicorp, Montréal, Canada) in blocking buffer for 24 h at 41C, washed and exposed to a 1:50 dilution of a biotinylated anti-mouse antibody (Vector Laboratories, Burlingame, CA, USA) for 1 h at room temperature. Sections were washed, incubated for 30 min with avidin-biotin-peroxidase reagent (Vectastain Elite ABC kit; Vector Laboratories), washed and exposed to diaminobenzidine (Vector Laboratories). Control tissues for the primary antibodies included lapine skin and lapine articular cartilage. To control for secondary immunoglobulins, sections were processed as above with omission of the primary antibody.
Evaluation of the sections
Serial histological sections of the distal femora were taken at 200 mm intervals. All sections were taken within approximately 1.2 mm from the center of the defects (n ¼ 5-10 per defect). Two individuals with no knowledge of the treatment groups independently graded all sections using an articular cartilage repair scoring system. 5 Specific parameters evaluated in this system include defect filling, integration, safranin O staining, cell morphology, defects architecture, surface architecture, subchondral bone and tidemark formation (Table  3) . Each section was scored and all scores for each treatment group were combined to determine the mean score for each group. A total of 181 sections were scored.
In each joint, the synovium was evaluated using a separate scoring system. 6 The three categories in this scoring system include villus thickening (fibrosis), villus architecture (blunting) and the presence of inflammatory cell infiltrates.
The area occupied by lacZ and IGF-I implants was measured from hematoxylin and eosin-stained serial histological sections of the distal femora that were taken at 400 mm intervals. Sections were taken within approximately 1.2 mm from the center of the defects (n ¼ 4-6 per defect). Low-magnification images of the cartilage defects were acquired by a solid-state CCD camera (Olympus, Hamburg, Germany) mounted on a microscope (BX 45; Olympus, Hamburg, Germany) and analyzed with the analySIS program (Soft Imaging System Corp., Mü nster, Germany).
Statistical analysis
On the basis of literature values for selected cartilage repair procedures, a standard deviation of 25% for the mean total score was estimated to determine the sample size. For a power of 80% and a two-tailed a level of 0.05, a sample size of six animals per group would be required to detect a mean difference of 5 points between the groups assuming a pooled standard deviation of 2.5 points (effect size ¼ 5/2.5 ¼ 2.0, using the two-sample Student's t-test (version 5.0, nQuery Advisor, Statistical Solutions, Saugus, MA, USA).
Each test condition was performed in quadruplicate for in vitro characterization experiments and with six defects per group and time point for in vivo experiments. To evaluate the in vivo experiments, points for each category and total score were compared between the two groups using a mixed general linear model with repeated-measures (knees nested within the same animals). Data are expressed as mean 795% confidence interval. A two-tailed Po0.05 was considered statistically significant.
